# Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

> **NCT00992602** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 3 (actual)

## Conditions studied

- Central Nervous System Metastases
- Leptomeningeal Metastases
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Tumors Metastatic to Brain

## Interventions

- **DRUG:** methotrexate
- **DRUG:** liposomal cytarabine
- **OTHER:** quality-of-life assessment
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00992602
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-06
- **Final completion:** 2014-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2017-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992602, "Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00992602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*